E.A. SALNIKOVA, E.V. KUMIROVA

Federal Scientific-Clinical Center for Children’s Hematology, Oncology and Immunology named after Dmitriy Rogachev, 1 Samora Mashel Str., Moscow, Russian Federation, 117997 

Salnikova E.A. — Junior Researcher of Neuro-Oncology Department, pediatrician of In-house Department, tel. +7-926-222-57-44, e-mail: ea_gerasimova@mail.ru

Kumirova E.V. — D. Med. Sc., Head of Neuro-Oncology Department, tel. (495) 287-65-70, ext. 12-59, e-mail: ella.kumirova@fccho-moscow.ru

The molecular and genetic studies conducted over the past decades have greatly expanded our understanding of the pathogenesis of medulloblastoma and allowed to identify the prognostically favorable subgroups for certain categories of patients. However, children of younger age group are still at risk. This review focuses on the molecular and genetic characteristics of medulloblastoma and its features in children under five years of age.

Key words: children, medulloblastoma, molecular and genetic subgroups of medulloblastoma.

REFERENCES

1. Dhall G. Medulloblastoma. J Child Neurol, 2009, vol. 24, no. 11, pp. 1418-1430.
2. Jozwiak J., Grajkowska W., Wlodarski P. Pathogenesis of medulloblastoma and current treatment outlook. Med Res Rev, 2007, vol. 27, no. 6, pp. 869-890.
3. Rickert C.H., Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst, 2001, vol. 17, no. 9, pp. 503-511.
4. Bailey P., Cushing H. Medulloblastoma cerebelli: a common type of mid-cerebellar glioma of childhood. Neurol. Psychiatry, 1925, vol. 14, pp. 192-223.
5. Rutka J.T., Hoffman H.J. Medulloblastoma: a historical perspective and overview. Neurooncol, 1996, vol. 29, no. 1, pp. 1-7.
6. Malignancies in Russia in 2013 (morbidity and mortality). Ed. A.D Caprin, V.V. Starinskiy, G.V. Petrova, Moscow: Moscow Oncology Research Institute named after PA Herzen, 2015, 250 p.
7. von Hoff K., Rutkowski S. Medulloblastoma. Curr Treat Options Neurol, 2012, vol. 14, no.. 4, pp. 416-426.
8. Taylor M.D., Northcott P.A., Korshunov A. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol, 2012, vol. 123, no. 4, pp. 465-472.
9. Matuev K.B., Gorelyshev S.K., Shishkina L.V. et al. Biological characteristics and long-term results of treatment of brain tumors in infants. Questions of Neurosurgery named after NN Burdenko, 2014, vol. 78, no. 2, pp. 46-56.
10. Giangaspero F., Rigobello L., Badiali M. et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol, 1992, vol. 16, no. 7, pp. 687-693.
11. Brown H.G., Kepner J.L., Perlman E.J. et al. “Large cell/anaplastic” medulloblastomas: a Pediatric Oncology Group Study. Neuropathol Exp Neurol, 2000, vol. 59, no. 10, pp. 857-865.
12. Lamont J.M., McManamy C.S., Pearson A.D. et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res, 2004, vol. 10, no. 16, pp. 5482-5493.
13. McCabe M.G., Bäcklund L.M., Leong H.S. et al. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro Oncol, 2011, vol. 13, no. 4, pp. 376-383.
14. Tabori U., Baskin B., Shago M. et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. Clin Oncol, 2010, vol. 28, no. 8, pp. 1345-1350.
15. Clifford S.C., Lusher M.E., Lindsey J.C. et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 2006, vol. 5, no. 22, pp. 2666-2670.
16. Ramaswamy V., Remke M., Bouffet E. et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol, 2016, vol. 131, no. 6, pp. 821-831.
17. Louis D.N., Perry A., Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016, vol. 131, no. 6, pp. 803-820.
18. Jones D.T., Jäger N., Kool M. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, vol. 488, no. 7409, pp. 100-105.
19. Robinson G., Parker M., Kranenburg T.A. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, vol. 488, no. 7409, pp. 43-48.
20. Li K.K., Lau K.M., Ng H.K. Signaling pathway and molecular subgroups of medulloblastoma. Int J Clin Exp Pathol, 2013, vol. 6, no. 7, pp. 1211-1222.
21. Briscoe J., Thérond P.P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol, 2013, vol. 14, no. 7, pp. 416-429.
22. Dey J., Ditzler S., Knoblaugh S.E. et al. A distinct smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol Cell Biol, 2012, vol. 32, no. 20, pp. 4104-4115.
23. Cowan R., Hoban P., Kelsey A. et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer, 1997, vol. 76, no. 2, pp. 141-145.
24. Evans D.G., Farndon P.A., Burnell L.D. et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer, 1991, vol. 64, pp. 959-961.
25. Gajjar A.J., Robinson G.W. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol, 2014, vol. 11, no. 12, pp. 714-722.
26. Kool M., Korshunov A., Remke M. et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol, 2012, vol. 123, no. 4, pp. 473-484.
27. Northcott P.A., Dubuc A.M., Pfister S. et al. Molecular subgroups of medulloblastoma. Expert Rev Neurother, 2012, vol. 12, no. 7, pp. 871-884.
28. Gajjar A., Bowers D.C., Karajannis M.A. et al. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol, 2015, vol. 33, no. 27, pp. 2986-2998.
29. Goodrich L.V., Milenković L., Higgins K.M. et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science, 1997, vol. 277, no. 5329, pp. 1109-1113.
30. Lee Y., Kawagoe R., Sasai K. et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene, 2007, vol. 26, no. 44, pp. 6442-6447.
31. Hatton B.A., Villavicencio E.H., Tsuchiya K.D. et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res, 2008, vol. 68, no. 6, pp. 1768-1776.
32. Hallahan A.R., Pritchard JI., Hansen S. et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res, 2004, vol. 64, no. 21, pp. 7794-7800.
33. Rutkowski S., Cohen B., Finlay J. et al. Medulloblastoma in young children. Pediatr Blood Cancer, 2010, vol. 54, no. 4, pp. 635-637.
34. Northcott P.A., Hielscher T., Dubuc A. et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol, 2011, vol. 122, no. 2 — pp. 231-240.
35. Ellison D.W., Dalton J., Kocak M. et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol, 2011, vol. 121, no. 3, pp. 381-396.
36. Minde D.P., Radli M., Forneris F. et al. Large extent of disorder in Adenomatous Polyposis Coli offers a strategy to guard Wnt signalling against point mutations. PLoS One, 2013, vol. 8, no. 10,
37. Hamilton S.R., Liu B., Parsons R.E. et al. The molecular basis of Turcot’s syndrome. Engl. J. Med, 1995, vol. 332, no. 13, pp. 839-847.
38. Northcott P.A., Shih D.J., Peacock J. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, vol. 488, no. 7409, pp. 49-56.
39. Zhukova N., Ramaswamy V., Remke M. et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun, 2014, vol. 2, no. 1, pp. 174-185.
40. Pietsch T., Schmidt R., Remke M. et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol, 2014, vol. 128, no. 1, pp. 137-149.
41. Cho Y.J., Tsherniak A., Tamayo P. et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol, 2011, vol. 29, no. 11, pp. 1424-1430.
42. Northcott P.A., Lee C., Zichner T. et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, vol. 511, no. 7510, pp. 428-434.
43. Shin D.J., Northcott P.A., Remke M. et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol, 2014, vol. 32, no. 9, pp. 886-896.
44. Coluccia D., Figuereido C., Isik S. et al. Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm. Curr Neurol Neurosci Rep, 2016, 16, no. 5, pp. 43-54.